1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Ferring Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Ferring Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 36 pages

Ferring Pharmaceuticals, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Ferring Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Ferring Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ferring Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ferring Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Ferring Pharmaceuticals, Inc. - Brief Ferring Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ferring Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ferring Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ferring Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Ferring Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ferring Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ferring Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ferring Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ferring Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Ferring Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Ferring Pharmaceuticals, Inc. Snapshot 5
Ferring Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Ferring Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Ferring Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Ferring Pharmaceuticals, Inc. - Pipeline Products Glance 10
Ferring Pharmaceuticals, Inc. - Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
Ferring Pharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Ferring Pharmaceuticals, Inc. - Drug Profiles 13
barusiban 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
degarelix 3 Month Formulation 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
degarelix acetate 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
elobixibat 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
FE-999049 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
misoprostol 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
selepressin 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Ferring Pharmaceuticals, Inc. - Pipeline Analysis 22
Ferring Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 22
Ferring Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24
Ferring Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 25
Ferring Pharmaceuticals, Inc. - Recent Pipeline Updates 27
Ferring Pharmaceuticals, Inc. - Dormant Projects 33
Ferring Pharmaceuticals, Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables


Ferring Pharmaceuticals, Inc., Key Information 5
Ferring Pharmaceuticals, Inc., Key Facts 5
Ferring Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Ferring Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Ferring Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Ferring Pharmaceuticals, Inc. - Filed, 2013 10
Ferring Pharmaceuticals, Inc. - Phase III, 2013 11
Ferring Pharmaceuticals, Inc. - Phase II, 2013 12
Ferring Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 23
Ferring Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 24
Ferring Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 26
Ferring Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 27
Ferring Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 33
Ferring Pharmaceuticals, Inc., Other Locations 34

List of Figures


Ferring Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Ferring Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Ferring Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Ferring Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 22
Ferring Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 24
Ferring Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.